The month of January saw a smattering of investor and agency hires, as well as a couple of non-profit and professional organisation hires that we’re throwing in for completeness’ sake.
It’s honestly getting harder to separate AI-powered pharma companies from pharma-focused AI companies as AI becomes more and more embedded in biopharma operations.
As we hit the Q2/Q3 mark in this very hot summer, the hires chatter is not exactly heating up, but we did see a steady beat of news in July, including a lot of new CEOs.
We normally only segment our hires roundup into three categories, but for the May-June double issue we had enough non-profit, professional organisation, and government hires to spin them of
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.